healthpharma
Scinai Immunotherapeutics Ltd (NASDAQ: SCNI) unveiled promising preclinical outcomes for its innovative anti IL-17A/F antibody fragment (NanoAb) aimed at treating mild to moderate plaque psoriasis. The biotechnology firm’s shares experienced a significant surge of 55% this morning after the announcement, but despite this increase, they are still down approximately 35% from their highest point over the past 52 weeks. Why is it significant for Scinai stock?Dr. Tamar Ben-Yedidia, Chief Scientist at SCNI, highlighted the milestone achievement, confirming that the NanoAb effectively neutralizes bot...
Invezz
Pfizer Inc (NYSE: PFE) is in focus today after announcing plans of proceeding with a once-a-day formulation of danuglipron – its weight-loss drug. Encouraging data from an ongoing early-stage study informed its decision to move forward with that variant of its obesity pill. Pfizer stock is currently trading slightly below its price at the start of 2024. What’s next for Pfizer Inc in the obesity market?Pfizer tested more than one formulation of its weight-loss drug and picked the one that had “the most favourable profile”. The New York listed firm will conduct trials in the back half of this ye...
Invezz
Longeveron Inc (NASDAQ: LGVN) soared 100% on Wednesday after its Lomecel-B received RMAT designation from the Food & Drug Administration. Lomecel-B is the company’s investigational treatment for Alzheimer’s disease. Longeveron stock is still down about 60% versus the start of 2024. Why is it significant for Longeveron stock?The Regenerative Medicine Advanced Therapy designation comes with regulatory benefits that enable developers like LGVN to move faster in making their products available in the market. Lomecel-B met the success threshold in patients with mild AD in Clear Mind (Phase 2a trial...
Invezz
Soligenix Inc (NASDAQ: SGNX) reported positive interim data from a trial of its HyBryte therapy on Tuesday. HyBryte is the biopharmaceutical firm’s treatment for early-stage cutaneous T-cell lymphoma. Soligenix stock rallied a whopping 400% following the interim results today. Here’s why it matters for Soligenix stockSoligenix has so far enrolled six patients in the aforementioned clinical study. Three of them met the minimum threshold for the treatment to be called a success within eighteen weeks. The Nasdaq-listed firm is committed to signing up a total of 50 patients eventually to the ongoi...
Invezz
The Walgreens (NASDAQ: WBA) stock price has fallen apart. It has crashed in the past three consecutive weeks and moved to its lowest point since 1998. The stock has plunged by more than 85% from its highest point in 2015. This means that a $10,000 invested in the stock in 2015 would be worth less than $1,500. Why Walgreens is implodedWalgreens Boots Alliance, the second-biggest pharmacy chain the US, has become a fallen angel that was recently booted from the Dow Jones index. This performance happened even after the company’s annual revenue rose from over $120 billion in 2017 to over $139 bill...
Invezz
Shares of Annovis Bio Inc (NYSE: ANVS) more than doubled on Tuesday after the biotech firm reported positive late-stage data for buntanetap. Buntanetap is the candidate treatment of ANVS for Parkinson’s disease. At the time of writing, Annovis stock is trading at $10.50 – still down some 45% versus the start of 2024. What does the data mean for Annovis stock?Buntanetap was shown to be effective in improving motor and nonmotor activities in a Phase 3 trial. It helped patients of Parkinson’s with overall cognitive function as well. Maria Maccecchini – the chief executive of Annovis Bio said in a...
Invezz
Eli Lilly & Co (NYSE: LLY) received approval for its Alzheimer’s drug from the Food & Drug Administration on Tuesday. The development is significant as it expands treatment options for the neurological disorder that affects close to 7 million Americans. At the time of writing, Eli Lilly shares are exchanging hands at $910. The pharma stock has gained more than 50% since the start of 2024. Is Kinsula news significant for Eli Lilly stock?Alzheimer’s is among the top five causes of deaths for Americans aged more than 65. More importantly, the number of patients suffering from this mind-wasting di...
Invezz
Humacyte Inc (NASDAQ: HUMA) opened close to 25% up on Monday after the Food & Drug Administration granted its ATEV a special advanced-therapy designation. Shares of the biotech firm are still down some 30% versus their year-to-date high. Why does it matter for Humacyte stock?The Acellular Tissue Engineering Vessel of the company based out of North Carolina, United States caters to patients with advanced peripheral artery disease. ATEV is implantable and is used in vascular replacement and repair. Dr. Cindy Cao – the chief regulatory officer of Humacyte said in a press release today: We are exc...
Invezz
The probability of Donald Trump returning to the White House currently sits at about 60%, as per Andrew Lilley – the chief interest rate strategist at Barrenjoey. And if Joe Biden’s Republican rival does indeed win the 2024 U.S. elections, the following three health insurance stocks will likely benefit. Why may health insurance stocks benefit from Trump’s victory?The chances of Donald Trump securing a second term have increased about 5.0% since his debate with President Joe Biden on Thursday (June 27). If he does indeed return to office in November, Medicare Advantage stocks will rally, said B...
Invezz
CVS Health (NYSE: CVS) stock price is imploding as concerns about the pharmacy business continue. It has already plunged by more than 43% from its 2022 highs and is hovering at its lowest point since November 2020. Pharmacy woes are continuingThe pharmacy industry is not doing well as the biggest players in the industry face unprecedented competition and other challenges. Rite Aid, the third-biggest pharmacy chain in the US filed for bankruptcy amid rising debt levels and slow growth. On Thursday, Walgreen’s stock price fell apart as it crashed by over 30% after the company published weak resu...
Invezz
閲覧を続けるには、ノアドット株式会社が「プライバシーポリシー」に定める「アクセスデータ」を取得することを含む「nor.利用規約」に同意する必要があります。
「これは何?」という方はこちら